Pentadeca Arginate vs TB-500
A rebranded BPC-157 salt with almost no literature of its own, against a peptide whose single randomized human result is about an eye drop.
Short answer
Both rest mostly on animal and lab work, so the evidence cannot separate pentadeca arginate from TB-500. Pentadeca arginate is the one sold for healing and recovery, while TB-500 targets recovery and tissue repair. Both are sold gray-market as research chemicals.
Pentadeca Arginate
PDA
Marketed as a more stable upgrade on BPC-157, but it has almost no research of its own — the evidence base is borrowed and preclinical.
Full Pentadeca Arginate evidence reviewTB-500
Thymosin β4
Mechanistic and early-stage human work (e.g. ophthalmology); no performance or recovery outcome trials.
Full TB-500 evidence reviewPentadeca Arginate vs TB-500: head to head
- FDA status / approved use
Pentadeca Arginate
Not an approved drug anywhere; sold online as research use onlyTB-500
Not an approved drug; prohibited in sport by WADA- Marketed for
Pentadeca Arginate
Healing, recovery (a 'stable BPC-157')TB-500
Recovery, tissue repair- Outcome areas
Pentadeca Arginate
Injury recovery / tissue repairTB-500
Injury recovery / tissue repair- Evidence grade
Pentadeca Arginate
Preclinical / minimalTB-500
Preclinical / minimal- How it works
Pentadeca Arginate
Arginate-salt form of a BPC 157-like peptide; benefits extrapolated from BPC 157TB-500
Binds and sequesters G-actin, regulating the cytoskeleton and cell migration- Route and dosing
Pentadeca Arginate
Injected; no established doseTB-500
Injectable; no established dose- Headline human result
Pentadeca Arginate
Not establishedTB-500
Not established- Strongest evidence
Pentadeca Arginate
Sikiric, Inflammopharmacology 2024. Little or no controlled human outcome data for the marketed usePentadeca Arginate evidence reviewPubMed 38980576TB-500
Expert Opin Biol Ther, 2018. Little or no controlled human outcome data for the marketed useTB-500 evidence reviewPubMed 30063853- Key safety signal
Pentadeca Arginate
Unknown purity, sterility and dosing; no direct human or animal studiesTB-500
No human efficacy trials, established dose or long-term safety data for the injectable- How it is obtained
Pentadeca Arginate
Sold gray-market as a research chemical; no approved or legitimately compounded human productTB-500
Sold gray-market as a research chemical; no approved or legitimately compounded human product
| Pentadeca Arginate | TB-500 | |
|---|---|---|
| FDA status / approved use | Not an approved drug anywhere; sold online as research use only | Not an approved drug; prohibited in sport by WADA |
| Marketed for | Healing, recovery (a 'stable BPC-157') | Recovery, tissue repair |
| Outcome areas | Injury recovery / tissue repair | Injury recovery / tissue repair |
| Evidence grade | Preclinical / minimal | Preclinical / minimal |
| How it works | Arginate-salt form of a BPC 157-like peptide; benefits extrapolated from BPC 157 | Binds and sequesters G-actin, regulating the cytoskeleton and cell migration |
| Route and dosing | Injected; no established dose | Injectable; no established dose |
| Headline human result | Not established | Not established |
| Strongest evidence | Sikiric, Inflammopharmacology 2024. Little or no controlled human outcome data for the marketed usePentadeca Arginate evidence reviewPubMed 38980576 | Expert Opin Biol Ther, 2018. Little or no controlled human outcome data for the marketed useTB-500 evidence reviewPubMed 30063853 |
| Key safety signal | Unknown purity, sterility and dosing; no direct human or animal studies | No human efficacy trials, established dose or long-term safety data for the injectable |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Sold gray-market as a research chemical; no approved or legitimately compounded human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Preclinical / minimal:
- Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.
Our verdict
TB-500 is the better-documented molecule, though not for the reason it is sold. Thymosin beta-4 has Phase 2 randomized data in severe dry eye using an ophthalmic solution, plus preclinical work in stroke, traumatic brain injury and cardiac repair; the injectable TB-500 marketed for muscle and tendon recovery has no published human efficacy trials, no established dosing, and is prohibited in sport by WADA. Pentadeca arginate has essentially no direct research at all and inherits its entire case from BPC-157's rodent studies. Neither is an approved drug, they have never been compared directly, and neither has human recovery outcomes.
Pentadeca Arginate fits if
Hard to justify on evidence; if the BPC-157 mechanism is what interests you, read the parent molecule rather than its arginate rebrand.
TB-500 fits if
Someone curious about actin-sequestering repair biology or the dry-eye program, who keeps that narrow clinical result separate from the recovery marketing.
Pentadeca Arginate vs TB-500: common questions
- Is either pentadeca arginate or TB-500 FDA-approved?
- No. Pentadeca arginate is not an approved drug anywhere; sold online as research use only. TB-500 is not an approved drug; prohibited in sport by WADA.
- Which has stronger human evidence, pentadeca arginate or TB-500?
- Neither. Both are graded preclinical / minimal, with little or no controlled human outcome data for the marketed use. The key source for pentadeca arginate is Sikiric, Inflammopharmacology 2024; for TB-500, it is Expert Opin Biol Ther, 2018.
- What are the main safety concerns with pentadeca arginate and TB-500?
- For pentadeca arginate, watch for unknown purity, sterility and dosing; no direct human or animal studies. TB-500 has no human efficacy trials, established dose or long-term safety data for the injectable.
Key studies behind each
Pentadeca Arginate
- Sikiric P, Sever M, Krezic I, et al. (2024). New studies with stable gastric pentadecapeptide protecting gastrointestinal tract: significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Inflammopharmacology. PubMed 38980576
- Gwyer D, Wragg NM, Wilson SL. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. PubMed 30915550
- McGuire FP, Martinez R, Lenz A, et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. PubMed 40789979
- Bilic Z, Gojkovic S, Kalogjera L, et al. (2021). Novel insight into Robert's cytoprotection: complex therapeutic effect of cytoprotective pentadecapeptide BPC 157 in rats with perforated stomach through modulation of the nitric-oxide system. J Physiol Pharmacol. PubMed 35485358
TB-500
- Sosne G. (2018). Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther. PubMed 30063853
- Sosne G, Dunn SP, Kim C. (2015). Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. PubMed 25826322
- Sosne G, Ousler GW. (2015). Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. PubMed 26056426
- Xiong Y, Mahmood A, Meng Y, et al. (2012). Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. Ann N Y Acad Sci. PubMed 23050817
The full evidence reviews
- Pentadeca Arginate (PDA): the evidence behind the BPC 157 successor
PDA is marketed as a more stable upgrade on BPC 157 — but it has almost no research of its own. A straight read of a borrowed evidence base.
Updated August 2026
- TB-500 and thymosin beta-4: separating the trials from the hype
Real Phase 2 dry-eye data, deep preclinical neuro/cardiac work, and a recovery-market use that was never actually tested.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm Pentadeca Arginate availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: RxSaludableRylo HealthRyze RxSpryStackMDSynergenX Health